anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
slides · global inventory

Callout

Component collection for the active corpus filters, with each row opening the slide detail view.

Search Insights JSON Unlock
Matching slides 96,741
Current window 74,521-74,550
Pages 3,225
Rows per page 30
Component: Calloutclear collectionreset all
18 30 60

Component

74,521-74,550 of 96,741

filter-aware
209
The slide uses a table to contrast the clinical trial design with the author's thesis that the evidence standard is too low.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
210
The slide uses a table of clinical trials alongside red-text annotations to highlight the geographic and temporal distance of the studies.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
213
The slide uses a combination of narrative text and specific evidence (EMA table and ClinicalTrials.gov record) to prove the existence of a suppressed trial.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
215
The slide functions as a 'fraud-exposure' or 'villain-critique' framework, systematically dismantling the credibility of the clinical trial data.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
216
This slide serves as a critical audit of clinical trial integrity, focusing on statistical manipulation and poor trial design.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
218
The slide uses visual evidence of four different versions of the ESS form to support the claim that the scale lacks a single, consistent format.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
219
The slide uses a 'villain' framing for the Epworth Sleepiness Scale to justify why it should not be used in the context of the research.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
220
The slide uses a critical tone to re-evaluate clinical trial data, highlighting the gap between statistical results and clinical meaningfulness.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
221
The slide uses clinical trial data to undermine the efficacy claims of a drug by highlighting the placebo response.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
225
The slide uses a strong, accusatory tone to undermine the validity of the clinical trial results.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
226
The slide uses a direct quote from a Lancet letter to undermine the credibility of the HARMONY 1 trial investigators.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
227
The slide highlights a discrepancy between the reported trial results and the underlying patient-level data regarding dosage and efficacy.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
232
The slide highlights a discrepancy between raw ESS scores and adjusted LS means, accusing the sponsor of data manipulation.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
235
The slide uses a strong, accusatory tone ('sycophancy', 'red flags') to frame the FDA's regulatory process as flawed.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
236
The slide uses a pie chart to visualize the geographic concentration of trial participants, specifically pointing out the high percentage in Russia to support a claim of data manipulation.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
240
The slide uses ClinicalTrials.gov record history to demonstrate a 'red flag' in trial reporting.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
242
The slide uses a CONSORT-style flow diagram to illustrate patient attrition in a clinical trial.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
243
The slide uses red boxes and text annotations to highlight specific data points (M6 for ESS, M12 for cataplexy) that contradict expected outcomes.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
244
The slide uses a comparative analysis of clinical trial data to challenge the validity of the HARMONY 3 results.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
245
The slide uses red text and boxes to emphasize the contradiction between the trial paper's claims and the EMA's findings.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
246
This slide appears to be a transition or setup slide for a quote or testimonial that is currently missing or intentionally blank.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
247
The slide serves as a qualitative research summary based on 16 expert interviews.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
248
This slide presents a series of critical findings regarding market performance, competitive positioning, safety concerns, and marketing practices for the drug Wakix.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
249
The slide presents qualitative interview summaries as evidence of poor market reception.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
250
The slide presents anecdotal evidence from four specific prescribers, highlighting skepticism, reimbursement hurdles, and varying levels of adoption.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
251
The slide presents qualitative interview summaries highlighting drug discontinuation, safety concerns, and competitive disadvantages.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
252
The slide presents qualitative interview data from four distinct medical professionals, highlighting skepticism, lack of efficacy, and safety concerns.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
253
The slide presents a qualitative anecdote from a physician interview regarding drug safety.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
254
The slide uses direct quotes from a KOL to undermine the market potential of Wakix.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
255
The slide uses a Q&A format to present qualitative feedback from a medical expert.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit